A‐85380: A Pharmacological Probe for the Preclinical and Clinical Investigation of the α4β2 Neuronal Nicotinic Acetylcholine Receptor
- 1 June 2006
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 12 (2), 100-112
- https://doi.org/10.1111/j.1527-3458.2006.00100.x
Abstract
A-85380 [3-(2(s)-azetidinylmethoxy) pyridine] is a neuronal nicotinic acetylcholine receptor (nAChR) agonist that has been a useful tool in the investigation of the function of nAChRs in both preclinical and clinical studies. Amongst nAChR subtypes, A-85380 shows selectivity for the alpha(4)beta(2) vs. the alpha(7) or alpha(1)beta(1)deltagamma nAChRs. In functional in vitro cation flux assays, A-85380 is a potent and full agonist. A-85380 has a broad-spectrum analgesic profile with efficacy in acute, persistent, and neuropathic pain models. As demonstrated using selective nAChR antagonists or alpha(4) antisense, the alpha(4)beta(2) nAChR mediates the analgesic effects of A-85380. Interestingly, the site of action depends upon the type of pain as antinociception is mediated by descending inhibition into the spinal cord whereas anti-allodynia in neuropathic pain is mediated at both central and peripheral sites. Radiolabelled forms of A-85380 have been developed and shown to be safe for use in vivo in humans. In clinical studies using positron and photon emission tomography, marked decreases in alpha(4)beta(2) nAChRs have been seen in patients with Parkinson's and Alzheimer's disease. Although not developed as a therapeutic agent, A-85380 has proven to be an important component in the development of novel nAChR ligands for the treatment of pain and other disorders.Keywords
This publication has 49 references indexed in Scilit:
- Autoradiography of 2‐[18F]F‐A‐85380 on nicotinic acetylcholine receptors in the porcine brain in vitroSynapse, 2005
- Widespread decrease of nicotinic acetylcholine receptors in Parkinson's diseaseAnnals of Neurology, 2005
- Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studiesNuclear Medicine and Biology, 2005
- The subunit composition and pharmacology of α-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assayNeuropharmacology, 2005
- Neuronal nicotinic acetylcholine receptor ligands as potential analgesicsExpert Opinion on Therapeutic Patents, 2003
- Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380Synapse, 2003
- Synthesis of [18F]FETO, a novel potential 11‐β hydroxylase inhibitorJournal of Labelled Compounds and Radiopharmaceuticals, 2003
- Pharmacology, toxicology, and radiation dosimetry evaluation of [123I]5-I-A-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humansDrug Development Research, 2003
- A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligandNeuropharmacology, 1996
- A-85380 [3-(2(S)-Azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligandNeuropharmacology, 1996